search Linkedin
Linkedin hamburger search

IL-15 Superagonist SOT101

SOT101 (formerly SO-C101) (RLI-15) is a subcutaneously-administered IL-15 superagonist that is fused to the IL-15α chain receptor. The drug has been precisely designed and optimized for its use as a potent immunotherapy by addressing two important design issues that limit current IL-2 and IL-15 approaches:

  1. Specificity for cytotoxic T and NK cells may provide superior efficacy and safety profile:
    SOT101 is designed to selectively bind only to cytotoxic T and NK cells, while avoiding other cell types that are associated with adverse events
  2. Optimized half-life may improve efficacy by limiting T cell exhaustion:
    SOT101’s pharmacokinetic properties enable it to ideally stimulate T and NK cells through pulses in cytokine concentration, rather than tonic stimulation

SOT101 has demonstrated strong preclinical in vivo efficacy in various tumor models showing increased long-term survival and tumor regression, as well as a favorable toxicology profile. SOT101 has also demonstrated potential for a combination approach with checkpoint inhibitors and ADCC monoclonal antibodies. 

SOTIO is conducting an ongoing Phase 1/1b study at leading clinical centers in the U.S. and EU, to examine SOT101 as monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors. More information on the ongoing clinical trial can be found here. We are planning to launch additional Phase 2 clinical trials in 2022.

SOTIO Biotech a.s.
Jankovcova 1518/2
170 00 Prague 7
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
SOTIO Biotech Representative Office
Beijing Lufthansa Center, Office C214
No. 50 Liangmaqiao Road
Beijing 100125
China
Sotio member of ppf group
Term of use Data protection Cookies Policy Cookie settings Site map © 2013 - 2022 Sotio
Sotio member of ppf group
Sitemap Terms of Use and Privacy
© 2013 - 2022 Sotio